Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
25.60
-1.16 (-4.33%)
At close: Dec 17, 2025, 4:00 PM EST
25.66
+0.06 (0.23%)
Pre-market: Dec 18, 2025, 7:33 AM EST
Beam Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Beam Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $48.09, which forecasts a 87.85% increase in the stock price over the next year. The lowest target is $21 and the highest is $80.
Price Target: $48.09 (+87.85%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Beam Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 3 | 4 | 5 | 5 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $35 | Buy | Initiates | $35 | +36.72% | Nov 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +212.50% | Oct 10, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $48 → $46 | Buy | Maintains | $48 → $46 | +79.69% | Oct 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +212.50% | Sep 15, 2025 |
| Barclays | Barclays | Hold Maintains $25 → $21 | Hold | Maintains | $25 → $21 | -17.97% | Aug 6, 2025 |
Financial Forecast
Revenue This Year
37.98M
from 63.52M
Decreased by -40.21%
Revenue Next Year
48.05M
from 37.98M
Increased by 26.52%
EPS This Year
-4.58
from -4.58
EPS Next Year
-4.73
from -4.58
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 53.1M | 115.5M | ||||
| Avg | 38.0M | 48.0M | ||||
| Low | 15.7M | 29.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -16.4% | 204.1% | ||||
| Avg | -40.2% | 26.5% | ||||
| Low | -75.3% | -22.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -4.43 | -3.71 | ||||
| Avg | -4.58 | -4.73 | ||||
| Low | -4.81 | -5.96 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.